Global cross functional development team leader for neuroscience and oncology development programs leading teams through creation and execution of integrated drug development strategies leveraging novel protein degradation modalities for patients diagnosed with lymphoma, solid tumors, Parkinson's disease and progressive supranuclear palsy.Assets: ARV-393 BCL6 degrader for B-cell lymphomas; ARV-102 LRRK2 degrader for Parkinson’s disease and Progressive Supranuclear Palsy; Undisclosed oncology target

Global cross functional development leader for oncology development programs leading teams through creation and execution of integrated drug development strategies leveraging novel adoptive T-cell receptor therapies for patients diagnosed with solid tumor cancers.Assets: MAGE-A4 afami-cel T-cell therapy in combination w/ radiation and anti-PD1 for the treatment of squamous cell carcinomas; partnered undisclosed multi-target T-cell therapies

Global CMC team leader for multiple small molecule programs, overseeing the development and commercialization of therapies for oncology, immunology, metabolism, infectious disease and neuroscience from preclinical through clinical and post-launch stages.Developed integrated CMC project plans, including risk management strategies, timelines, and budgets, driving the successful execution of multiple programs across various stages of development.Assets: Ph1-3 development of Orexin-2 agonist for patients with major depressive disorder with insomnia symptoms (Seltorexant); Ph1-2 development of IL-23 pathway therapies for patients with Crohn’s disease and ulcerative colitisPh1 development of BTK inhibitor for patients with hematological malignancies; Ph3 development/ commercialization of EGFR TKI inhibitor for patients with NSCLC (Lazcluze™); Ph3 development/ commercialization of chemotherapy for patients with sarcoma or ovarian cancer (Yondelis®); life-cycle management of Factor X inhibitor to prevent blood clotting (Xarelto®)

Directed technical projects encompassing transfer, process development, commercial manufacturing, quality/regulatory oversight, and product lifecycle management. Led cross-functional teams in all facets of CMC and regulatory drug development and manufacturing. Alliance Manager and primary point of contact for biotech/pharmaceutical partner companies, facilitating product development across all phases of clinical trials and commercial launches. Assets: Xyrem® for the treatment of cataplexy and excessive daytime sleepiness for patients with narcolepsy; Auryxia® treating hyperphosphatemia and iron deficiency anemia in patients with CKD

Areas of Expertise: High pressure and super-critical Chemistry, Solid State Chemistry & Crystallization, Advanced material characterization methodsDissertation: High pressure growth of silicon wires inside microstructured optical fibers

Production operator in drug substance manufacturing